Ciclodin IV Infusion Bag

Susceptible microorganisms eg, E. coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus (indole +ve & -ve), Pseudomonas, Neisseria, Acinetobacter, Strep, Chlamydia, Staph, Corynebacterium, Bacteroides, Clostridium. Infectious diseases eg, resp tract, ENT, kidney or urinary tract, genital tract (including gonorrhea), GIT, biliary tract, skin & soft tissue, bones & joints & gynecological infections, sepsis & peritonitis.

Administer by IV infusion over 60 min. Duration: 7-14 days. Bone or joint infection: ≥4-6 wk; in addition, administer for 2 days following after symptoms of infection are resolved. Adult 100-400 mg bid. Mild to moderate UTI 200 mg bid. Severe or complicated UTI 400 mg bid. Mild to moderate lower resp tract, skin or skin tissue, or bone & joint infection 400 mg bid. Severe lower resp tract, skin or skin tissue, or bone & joint infection 400 mg tid. Renal impairment CrCl ≥30 mL/min Usual dose, 5-29 mL/min 200-400 mg every 18-24 hr.

Hypersensitivity to ciprofloxacin or any quinolones. Patients w/ epilepsy; history of tendon ruptures or tendonitis associated w/ quinolones or ciprofloxacin. Concomitant use w/ tizanidine; ketoprofen. Women of childbearing potential. Pregnancy or lactation. Childn or growing adolescents <18 yr.

Discontinue use at 1st signs or symptoms of any serious adverse reactions eg, tendinitis & tendon rupture, peripheral neuropathy, CNS effects; in case of depression, psychotic reactions, suicidal ideation & actions; suspected pseudomembranous colitis; any signs for phototoxicity reactions (ie, rash, eruptions, pruritus); any signs & symptoms of hepatitis; hypotensive, dyspnea, feeling of chest pressure; symptoms of interstitial pneumonia. Avoid use in patients who have or at risk for aortic aneurysm eg, patients w/ peripheral atherosclerotic vascular disease, HTN, Marfan & Ehlers-Danlos syndrome; known history of myasthenia gravis. Not suited for monotherapy of severe infections & infections that might be due to gram +ve or anaerobic pathogens. Not recommended for streptococcal infections. Recommended to be used for min period required for treatment to reduce development of drug-resistant bacteria. Ciprofloxacin use should only be considered for genital tract infections when combined w/ other appropriate antibacterial agents, unless ciprofloxacin-resistant N. gonorrhoeae can be excluded. Potential risk of convulsion in patients w/ history of convulsive diseases; or known or suspected CNS disorders eg, severe cerebral arteriosclerosis. Risk of rhabdomyolysis accompanied w/ acute decline in renal function; may worsen symptoms of myasthenia gravis in patients w/ myasthenia gravis. Reports of crystalluria in excessive administration; sensory or sensorimotor polyneuropathy triggering dysesthesia, hypoesthesia, & perception disorder; local IV site reactions. Rhabdomyolysis accompanied w/ acute decline in renal function. Crystalluria in excessive administration. Patients w/ vein disorders; known prolongation of the QT interval, risk factors for QT interval prolongation or torsade de pointes. Reserve use in patients who have no alternative treatment for acute bacterial sinusitis & exacerbation of chronic bronchitis, uncomplicated UTI. Minimize or avoid exposure to excessive natural or artificial UV light eg, sunlight lamps or tanning beds. Monitor for rare shock. Concomitant use w/ theophylline; phenylacetate (eg, fenbufen, flubiprofen) or propionate NSAID; class IA (eg, quinidine, procainamide) or III (eg, amiodarone, sotalol) antiarrhythmics. May give false -ve bacteriological test results for Mycobacterium tuberculosis. Patients w/ vein disorders; known prolongation of the QT interval, risk factors for QT interval prolongation or torsade de pointes; G6PD deficiency; patients for whom Na intake is of medical concern eg, patients w/ CHF, renal failure, nephrotic syndrome. May affect ability to drive or operate machinery, especially when taken w/ alcohol. Patients w/ severe renal impairment. Elderly.

Nausea, diarrhea.

Increased plasma conc of CYP1A2 substrates eg, theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine. Rarely, seizures w/ ketoprofen; phenylacetic acid-derived (eg, fenbufen, flubiprofen) or propionic acid-derived NSAIDs. Slightly diminished C_max & AUC w/ omeprazole. May augment anticoagulant effects of warfarin. Hypoglycemia (sometimes severe) w/ oral antidiabetic agents, mainly sulfonylureas (eg, glyburide, glimepiride). May increase serum conc of cyclosporine & elevate serum creatinine. Renal tubular secretion may be interfered by probenecid. May inhibit renal tubular transport of MTX. Increased serum conc of tizanidine; clozapine & N-desmethylclozapine. May increase or reduce serum levels of phenytoin. Reduced clearance resulting in elevated levels & prolongation of serum t_1/2 of caffeine or pentoxifylline. Increased C_max & AUC of ropinirole. Reduced clearance of IV lidocaine. Caution w/ concomitant use of drugs known to prolong QT interval eg, class IA & III antiarrhythmic. Increased serum level & AUC of sildenafil. Risk of increased serum level of zolpidem.

Quinolones

J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Rx